This Amendment No. 4 (this Amendment) amends and supplements the Tender
Offer Statement on Schedule TO filed by MorphoSys Development Inc., a Delaware corporation (Purchaser), and MorphoSys AG, a German stock corporation (Aktiengesellschaft) (Parent), with the U.S. Securities and
Exchange Commission on June 16, 2021 (together with any subsequent amendments and supplements thereto, the Schedule TO). The Schedule TO relates to the offer by Purchaser to purchase all outstanding shares of common stock, $0.0001
par value per share (the Shares), of Constellation Pharmaceuticals, Inc., a Delaware corporation (the Company), at a price of $34.00 per Share, net to the holder in cash, without interest and subject to any withholding of
taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated June 16, 2021 (together with any amendments or supplements thereto, the Offer to Purchase) and in the accompanying Letter of Transmittal
(together with any amendments or supplements thereto and with the Offer to Purchase, the Offer), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and
(a)(1)(B), respectively. Purchaser is an indirect wholly
owned subsidiary of Parent. This Amendment is being filed on behalf of Parent and Purchaser. Unless otherwise indicated, references to sections in the Schedule TO are references to sections of the Offer to Purchase.
Amendments to the Offer to Purchase:
Items 1 through
11.
The information set forth in the Offer to Purchase and Items 1 through 11 of the Schedule TO, to the extent such Items incorporate
by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:
At one minute after
11:59 p.m., New York City time, on July 14, 2021, the Offer expired. The Depository advised Purchaser that, as of the expiration of the Offer, a total of 42,811,957 Shares were validly tendered and not validly withdrawn pursuant to the Offer,
representing approximately 89% of the Shares outstanding as of the expiration of the Offer.
As of the expiration of the Offer, the number
of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Tender Condition, and all other conditions to the Offer were satisfied or waived. Immediately after the expiration of the Offer, Purchaser irrevocably
accepted for payment, and will promptly (and in any event no later than the second business day after such acceptance) pay for, all Shares tendered and not validly withdrawn pursuant to the Offer.
Parent and Purchaser have completed the acquisition of the Company on July 15, 2021 by consummating the Merger pursuant to the Merger
Agreement at 7.45 a.m. New York City time without a meeting of the Company stockholders in accordance with Section 251(h) of the DGCL. At the effective time of the Merger, each outstanding Share (other than any Shares held by or in the treasury
of the Company or owned by Parent, Purchaser or any of Parents other subsidiaries and any Shares held by stockholders who have properly exercised and perfected their demands for appraisal of such Shares in accordance with the DGCL and have
neither withdrawn nor lost such rights prior to the effective time of the Merger) were cancelled and converted into the right to receive $34.00, net to the seller in cash, without interest, and subject to any applicable withholding of taxes.
Following the consummation of the Merger, the Shares will be delisted and will cease to trade on the Nasdaq Global Select Market. Parent and
the Company intend to take steps to cause the termination of the registration of the Shares under the Exchange Act and suspend all of the Companys reporting obligations under the Exchange Act as promptly as practicable.
Item 12
Item 12 of the Schedule TO is hereby
amended and supplemented by adding the following exhibit:
|
|
|
(a)(5)(K)
|
|
Press Release, dated July 15, 2021.
|